ABOUT VISIONAIRE

Advancing the next standard of care in anterior diagnostics

Visionaire Products creates devices that change how clinicians sample and analyze ocular fluid. OcuTap is a single-use tool with a simple attach-and-prime setup, designed for single-handed anterior chamber paracentesis, with a detachable vial that ships directly to the lab. We work closely with ophthalmologists and labs to meet clinical needs, validate with evidence, and build user-friendly devices.

Clinician-innovator driving device design

A board-certified ophthalmologist and Chief Executive Officer (CEO) and co-founder of Visionaire Products, she is a retina specialist with a Master of Business Administration (MBA) in healthcare marketing. Her career spans academic and private practice, with expertise in diagnosing and managing uveitis, where she frequently performs anterior chamber paracentesis. She has served as principal investigator on numerous national clinical trials, secured over $4.5 million in grant funding from the Defense Health Agency and National Science Foundation, and founded the ophthalmology research program at Carle Foundation Hospital. She also co-founded InnSight Technology and advises medical device companies on novel ophthalmology treatments. Trained at Duke, PCOM, UPMC, and USC's Doheny Eye Institute.

The team behind OcuTap

Rick Mental Director of Manufacturing · Project Manager

Brings 40+ years of experience launching and commercializing new technologies, including as General Manager of Nissha's printed electronics division. Since joining Visionaire in 2019, he has led manufacturing strategy, materials sourcing, and NSF Small Business Innovation Research (SBIR) Phase I/II grants, driving the OcuTap device toward successful commercialization.
Shaaz Nadeem R&D Engineer

Drives technical development across device design, testing, and technology commercialization. He led verification and validation efforts supporting FDA 510(k) submission of the OcuTap and leads early-stage design of Visionaire's next-generation ophthalmic diagnostic platform. He earned both Bachelor's and Master's degrees in Bioengineering from the University of Pittsburgh.
Dr. Jason Handza Clinical advisor

Serves as a strategic Clinical Advisor for Visionaire, lending clinical and industry expertise to OcuTap's development. Currently Chief Medical Officer at Nextech Systems and Partner at Sight360, he brings deep ophthalmic and anterior chamber procedural knowledge that helps refine the device's performance and path to commercialization.

Backed by rigorous science

Visionaire has secured $1.25 million in non-dilutive funding through the National Science Foundation (NSF) Small Business Innovation Research Phase I and Phase II awards. This funding reflects the NSF’s recognition of OcuTap’s technical merit and supports our work toward FDA clearance.

Stay informed on OcuTap’s regulatory progress.

OcuTap is pending U.S. Food and Drug Administration (FDA) clearance, anticipated by the end of 2026. Sign up to get updates and we’ll email you when there’s meaningful news to share.

REFERENCES & CITATIONS

National Science Foundation SBIR Phase I and Phase II awards.Visionaire Products, Inc. (2021, 2023). SBIR Phase I & Phase II: A novel, microfluidic device to improve collection and analysis of biopsy samples from ocular paracentesis. National Science Foundation. sbir.gov (opens in a new tab)